IP Library Granted Patent US 7,282,217
Granted Patent B1
US 7,282,217 · App. 10/929,856 · Granted Oct 16, 2007

Rapidly disintegrable tablets

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,282,217
App. No.
10/929,856
Granted
Oct 16, 2007
Kind
B1
Abstract

The invention provides a rapidly disintegrating tablet comprising an active ingredient, a water soluble, directly compressible carbohydrate, and a water soluble, directly compressible filler. Also provided is a method of producing a rapidly disintegrating tablet, which method comprises wet granulating a mixture comprising a directly compressible, water soluble carbohydrate, a directly compressible, water insoluble filler, a beneficial ingredient, and a solvent, and compressing the granulate to produce the tablet.

Claims (39)

1. A rapidly disintegrating tablet comprising a compressed granulate containing: (i) one or more beneficial ingredients; (ii) one or more directly compressible, water soluble carbohydrates; and (iii) one or more directly compressible, water insoluble fillers, wherein the tablet has a friability of at most about 1.5%, and a porosity of from about 15% to about 45%, wherein the tablet disintegrates rapidly in an aqueous medium.

2. The rapidly disintegrating tablet of claim 1 , wherein the one or more beneficial ingredients is selected from the group consisting of pharmaceutically active agents, nutraceutically active agents, and combinations thereof.

3. The rapidly disintegrating tablet of claim 1 , wherein the one or more beneficial ingredients comprises one or more pharmaceutically active agents.

4. The rapidly disintegrating tablet of claim 3 , wherein the one or more pharmaceutically active agents comprises hyoscyamine sulfate.

5. The rapidly disintegrating tablet of claim 1 , which is an orally disintegrating tablet.

6. The rapidly disintegrating tablet of claim 1 , which is a taste-masked rapidly disintegrating tablet.

7. The rapidly disintegrating tablet of claim 1 , wherein the active agent comprises a nutraceutically active agent.

8. The rapidly disintegrating tablet of claim 7 , wherein the nutraceutically active agent is sodium fluoride.

9. The rapidly disintegrating tablet of claim 1 , wherein the directly compressible, water soluble carbohydrate is selected from the group consisting of directly compressible mannitol, directly compressible sorbitol, directly compressible maltitol, directly compressible lactose, directly compressible sucrose, directly compressible xylose, directly compressible trehalose, directly compressible dextrose, and combinations thereof.

10. The rapidly disintegrating tablet of claim 9 , wherein the directly compressible, water soluble carbohydrate is a directly compressible mannitol.

11. The rapidly disintegrating tablet of claim 9 , wherein the mannitol comprises a directly compressible spray dried mannitol.

12. The rapidly disintegrating tablet of claim 1 , wherein the directly compressible, water soluble carbohydrate comprises a directly compressible granulate obtained by wet granulation of a directly compressible spray dried mannitol in the presence of the active ingredient and a solvent.

13. The rapidly disintegrating tablet of claim 12 , comprising a directly compressible granulate obtained by wet granulation of a directly compressible spray dried mannitol in the presence of the active ingredient and a solvent.

14. The rapidly disintegrating tablet of claim 12 , comprising a directly compressible granulate obtained by wet granulation of a directly compressible spray dried mannitol in the presence of the active ingredient and an aqueous solvent.

15. The rapidly disintegrating tablet of claim 12 , comprising a directly compressible granulate obtained by wet granulation of a directly compressible spray dried mannitol in the presence of the active ingredient and water.

16. The rapidly disintegrating tablet of claim 1 , wherein the directly compressible, water insoluble filler is a directly compressible, water insoluble polysaccharide.

17. The rapidly disintegrating tablet of claim 16 , wherein the directly compressible, water insoluble polysaccharide is a directly compressible cellulose.

18. The rapidly disintegrating tablet of claim 17 , wherein the directly compressible cellulose is microcrystalline cellulose.

19. The rapidly disintegrating tablet of claim 1 , wherein the friability of the tablet is not more than about 1%.

20. The rapidly disintegrating tablet of claim 1 , wherein the friability of the tablet is not more than about 0.5%.

21. The rapidly disintegrating tablet of claim 1 , wherein the porosity of the tablet is from about 15% to about 35%.

22. The rapidly disintegrating tablet of claim 1 , wherein the porosity of the tablet is from about 15% to about 25%.

23. The rapidly disintegrating tablet of claim 1 , wherein the porosity of the tablet is from about 20% to about 30%.

24. The rapidly disintegrating tablet of claim 1 , wherein the tablet has a density of from about 0.5 g/mL to about 2.5 g/mL.

25. A rapidly disintegrating tablet comprising a compressed granulate containing: (i) hyoscyamine; (ii) directly compressible spray-dried mannitol; and (iii) directly compressible microcrystalline cellulose, wherein the tablet has a friability of not more than about 1.5% and a porosity of from about 15% to about 45%, wherein the tablet disintegrates rapidly in an aqueous medium.

26. The rapidly disintegrating tablet of claim 25 , wherein the porosity of the tablet is from about 20% to about 30%.

27. A rapidly disintegrating tablet comprising a compressed granulate containing: (i) sodium fluoride; (ii) directly compressible spray-dried mannitol; and (iii) directly compressible microcrystalline cellulose, wherein the tablet has a friability of not more than about 1.5% and a porosity of from about 15% to about 45%, wherein the tablet disintegrates rapidly in an aqueous medium.

28. The rapidly disintegrating tablet of claim 27 , wherein the porosity of the tablet is from about 20% to about 30%.

29. A rapidly disintegrating tablet consisting essentially of a compressed granulate containing: (i) hyoscyamine; (ii) directly compressible spray-dried mannitol; (iii) directly compressible microcrystalline cellulose; (iv) crospovidone; (v) silicon dioxide; (vi) a lubricant; and, optionally, (vii) a sweetener; and (viii) a flavorant, wherein the tablet has a friability of not more than about 1.5% and a porosity of from about 15% to about 45%%, wherein the tablet disintegrates rapidly in an aqueous medium.

30. The rapidly disintegrating tablet of claim 29 , wherein the porosity of the tablet is from about 20% to about 30%.

31. A rapidly disintegrating tablet consisting essentially of a compressed granulate containing: (i) sodium fluoride; (ii) directly compressible spray-dried mannitol; (iii) directly compressible microcrystalline cellulose; (iv) crospovidone; (v) silicon dioxide; (vi) a lubricant; and, optionally, (vii) a sweetener; and (viii) a flavorant, wherein the composition has a friability of not more than about 1.5% and a porosity of from about 15% to about 45%%, wherein the tablet disintegrates rapidly in an aqueous medium.

32. The rapidly disintegrating tablet of claim 31 , wherein the porosity of the tablet is from about 20% to about 30%.

33. The rapidly disintegrating tablet of claim 1 , wherein the composition disintegrates in an aqueous medium from within about 2 seconds to within about 120 seconds.

34. The rapidly disintegrating tablet of claim 1 , wherein the composition disintegrates in an aqueous medium from within about 2 second to within about 60 seconds.

35. The rapidly disintegrating tablet of claim 1 , wherein the composition disintegrates in an aqueous medium from within about 2 second to within about 30 seconds.

36. The rapidly disintegrating tablet of claim 33 , wherein the aqueous medium comprises saliva.

37. The rapidly disintegrating tablet of claim 3 , wherein the one or more pharmaceutically active agents comprises ondansetron.

38. The rapidly disintegrating tablet of claim 3 , wherein the one or more pharmaceutically active agents comprises olanzapine.

39. The rapidly disintegrating tablet of claim 1 , wherein: (i) the one or more beneficial ingredients comprises one or more pharmaceutically active agents, (ii) the one or more directly compressible, water soluble carbohydrates consists essentially of directly compressible spray-dried mannitol, (iii) the one or more directly compressible, water insoluble fillers consists essentially of directly compressible microcrystalline cellulose, and the tablet further comprises (iv) crospovidone, (v) silicon dioxide, (vi) a lubricant, optionally (vii) a sweetener, and optionally (viii) a flavorant.

Assignments (16)
MERGER AND CHANGE OF NAME Recorded Jan 3, 2018
From: AMAG PHARMACEUTICALS IP, LTD.; AMAG PHARMA USA, INC.
To: AMAG PHARMA USA, INC.
Reel/Frame 044523/0160 →
CHANGE OF NAME Recorded Dec 27, 2017
From: LUMARA HEALTH IP LTD.
To: AMAG PHARMACEUTICALS IP, LTD.
Reel/Frame 044961/0232 →
RELEASE OF SECURITY INTEREST Recorded May 15, 2017
From: JEFFERIES FINANCE LLC
To: LUMARA HEALTH IP LTD.
Reel/Frame 042461/0626 →
RELEASE OF SECURITY INTEREST Recorded Oct 9, 2015
From: WILMINGTON TRUST, NATIONAL ASSOCIATION
To: LUMARA HEALTH IP LTD.
Reel/Frame 036763/0475 →
RELEASE OF SECURITY INTEREST Recorded Oct 1, 2015
From: WILLMINGTON TRUST, NATIONAL ASSOCIATION
To: LUMARA HEALTH IP LTD
Reel/Frame 036704/0822 →
SECURITY INTEREST Recorded Sep 25, 2015
From: LUMARA HEALTH IP LTD.
To: JEFFERIES FINANCE LLC
Reel/Frame 036653/0138 →
SECURITY INTEREST Recorded Nov 12, 2014
From: LUMARA HEALTH IP LTD
To: JEFFERIES FINANCE LLC
Reel/Frame 034156/0243 →
RELEASE OF SECURITY INTERESTS IN INTELLECTUAL PROPERTY Recorded Oct 20, 2014
From: LAW DEBENTURE TRUST COMPANY OF NEW YORK
To: K-V PHARMACEUTICAL COMPANY
Reel/Frame 034018/0040 →
CHANGE OF NAME Recorded Jul 9, 2014
From: DRUGTECH CORPORATION
To: LUMARA HEALTH IP LTD.
Reel/Frame 033282/0265 →
SECURITY AGREEMENT Recorded Sep 17, 2013
From: DRUGTECH CORPORATION
To: LAW DEBENTURE TRUST COMPANY OF NEW YORK, AS AGENT
Reel/Frame 031226/0883 →
RELEASE OF SECURITY INTEREST Recorded Mar 18, 2011
From: U.S. HEALTHCARE, LLC (AS ADMINISTRATIVE AND COLLATERAL AGENT)
To: DRUGTECH CORPORATION
Reel/Frame 025980/0024 →
SECURITY AGREEMENT Recorded Mar 18, 2011
From: DRUGTECH CORPORATION
To: WILMINGTON TRUST FSB (AS COLLATERAL AGENT)
Reel/Frame 025981/0068 →
RELEASE OF SECURITY INTEREST Recorded Mar 18, 2011
From: U.S. HEALTHCARE I, LLC (AS ADMINISTRATIVE AND COLLATERAL AGENT)
To: DRUGTECH CORPORATION
Reel/Frame 025981/0934 →
PATENT SECURITY AGREEMENT Recorded Nov 20, 2010
From: DRUGTECH CORPORATION
To: U.S. HEALTHCARE I, LLC
Reel/Frame 025385/0498 →
PATENT SECURITY AGREEMENT Recorded Sep 14, 2010
From: DRUGTECH CORPORATION
To: U.S. HEALTHCARE I, L.L.C.
Reel/Frame 024982/0344 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 10, 2010
From: KV PHARMACEUTICAL COMPANY
To: DRUGTECH CORPORATION
Reel/Frame 024964/0815 →